GSK (GSK) Stock Forecast, Price Target & Predictions
GSK Stock Forecast
GSK stock forecast is as follows: an average price target of $58.00 (represents a 57.27% upside from GSK’s last price of $36.88) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
GSK Price Target
The average price target for GSK (GSK) is $58.00 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $85.00 to $36.00. This represents a potential 57.27% upside from GSK's last price of $36.88.
GSK Analyst Ratings
According to 10 Wall Street analysts, GSK's rating consensus is 'Hold'. The analyst rating breakdown for GSK stock is 0 'Strong Buy' (0.00%), 3 'Buy' (30.00%), 7 'Hold' (70.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GSK Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 02, 2024 | Peter Welford | Jefferies | $53.00 | $38.38 | 38.09% | 43.71% |
| Apr 11, 2024 | Vamil Divan | Guggenheim | $36.00 | $40.69 | -11.53% | -2.39% |
| Apr 11, 2024 | Mark Purcell | Morgan Stanley | $85.00 | $40.69 | 108.90% | 130.48% |
The latest GSK stock forecast, released on Jul 02, 2024 by Peter Welford from Jefferies, set a price target of $53.00, which represents a 38.09% increase from the stock price at the time of the forecast ($38.38), and a 43.71% increase from GSK last price ($36.88).
GSK Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $58.00 |
| Last Closing Price | $36.88 | $36.88 | $36.88 |
| Upside/Downside | -100.00% | -100.00% | 57.27% |
In the current month, the average price target of GSK stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GSK's last price of $36.88. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| Oct 07, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 01, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 22, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Jul 08, 2024 | UBS | - | Neutral | Downgrade |
| Jul 02, 2024 | Jefferies | Buy | Buy | Hold |
| Jun 04, 2024 | Jefferies | Buy | Buy | Hold |
GSK's last stock rating was published by Guggenheim on Oct 31, 2024. The company Downgrade its GSK rating from "Buy" to "Neutral".
GSK Financial Forecast
GSK Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $6.95B | $7.38B | $7.83B | $6.93B | $9.78B | $9.53B | $9.08B | $8.09B | $7.42B | $8.74B | $8.65B | $7.62B | $9.09B | $8.90B | $9.38B | $7.81B | $7.66B |
| Avg Forecast | $10.91B | $10.91B | $10.47B | $9.87B | $10.09B | $10.52B | $9.57B | $8.89B | $9.66B | $9.37B | $8.78B | $8.07B | $8.90B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
| High Forecast | $11.00B | $11.00B | $10.55B | $9.95B | $10.16B | $10.60B | $9.65B | $8.96B | $9.70B | $9.52B | $8.85B | $8.13B | $8.97B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
| Low Forecast | $10.82B | $10.81B | $10.37B | $9.78B | $9.92B | $10.42B | $9.48B | $8.81B | $9.62B | $9.23B | $8.70B | $8.00B | $8.82B | $8.31B | $7.88B | $11.75B | $12.87B | $11.90B | $10.45B | $10.85B | $11.88B | $11.45B | $9.71B | $10.86B | $11.78B | $11.41B | $9.55B | $9.83B |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 0.83% | 0.94% | 0.88% | 0.83% | 0.74% | 0.76% | 0.77% | 0.68% | 0.74% | 0.76% | 0.79% | 0.84% | 0.76% | 0.82% | 0.82% | 0.78% |
GSK's average Quarter revenue forecast for Jun 23 based on 1 analysts is $8.78B, with a low forecast of $8.70B, and a high forecast of $8.85B. GSK's average Quarter revenue forecast represents a 26.36% increase compared to the company's last Quarter revenue of $6.95B (Mar 23).
GSK EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $2.75B | $1.90B | $2.17B | $1.73B | $3.51B | $1.74B | $2.93B | $2.36B | $2.08B | $3.71B | $2.51B | $2.87B | $2.26B | $1.20B | $2.71B | $2.28B | $2.70B |
| Avg Forecast | $3.08B | $3.08B | $2.96B | $2.79B | $2.85B | $2.97B | $2.70B | $2.51B | $2.73B | $2.65B | $2.48B | $2.28B | $2.52B | $2.35B | $1.47B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
| High Forecast | $3.11B | $3.11B | $2.98B | $2.81B | $2.87B | $3.00B | $2.73B | $2.53B | $2.74B | $2.69B | $2.50B | $2.30B | $2.54B | $2.35B | $1.77B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
| Low Forecast | $3.06B | $3.05B | $2.93B | $2.76B | $2.80B | $2.94B | $2.68B | $2.49B | $2.72B | $2.61B | $2.46B | $2.26B | $2.49B | $2.35B | $1.18B | $3.32B | $3.64B | $3.36B | $2.95B | $3.07B | $3.36B | $3.23B | $2.74B | $3.07B | $3.33B | $3.22B | $2.70B | $2.78B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 0.75% | 0.92% | 1.17% | 1.06% | 0.48% | 0.87% | 0.80% | 0.68% | 1.10% | 0.78% | 1.05% | 0.74% | 0.36% | 0.84% | 0.84% | 0.97% |
1 analysts predict GSK's average Quarter EBITDA for Jun 23 to be $2.48B, with a high of $2.50B and a low of $2.46B. This is -9.71% lower than GSK's previous annual EBITDA (Mar 23) of $2.75B.
GSK Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $1.49B | $1.50B | $779.00M | $838.00M | $1.80B | $930.00M | $1.17B | $1.40B | $1.07B | $677.00M | $1.24B | $2.26B | $1.56B | $1.30B | $1.55B | $964.00M | $830.00M |
| Avg Forecast | $1.27B | $2.06B | $1.95B | $1.92B | $882.79M | $1.76B | $1.58B | $1.50B | $1.19B | $1.87B | $1.44B | $1.37B | $907.07M | $3.35B | $677.29M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
| High Forecast | $1.29B | $2.08B | $1.97B | $1.94B | $1.00B | $1.80B | $1.58B | $1.50B | $1.25B | $1.89B | $1.45B | $1.38B | $916.49M | $3.35B | $812.75M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
| Low Forecast | $1.26B | $2.04B | $1.92B | $1.89B | $658.80M | $1.71B | $1.58B | $1.50B | $1.11B | $1.85B | $1.42B | $1.35B | $896.31M | $3.35B | $541.83M | $2.48B | $2.03B | $2.42B | $1.63B | $1.78B | $1.94B | $2.55B | $1.66B | $2.64B | $2.14B | $2.81B | $2.08B | $2.14B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.65% | 0.23% | 1.24% | 0.73% | 0.46% | 0.48% | 0.85% | 0.60% | 0.35% | 0.49% | 1.36% | 0.59% | 0.61% | 0.55% | 0.46% | 0.39% |
GSK's average Quarter net income forecast for Jun 23 is $1.44B, with a range of $1.42B to $1.45B. GSK's average Quarter net income forecast represents a -3.45% decrease compared to the company's last Quarter net income of $1.49B (Mar 23).
GSK SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $2.14B | $2.44B | $2.06B | $2.07B | $2.84B | $3.26B | $2.65B | $2.64B | $2.43B | $3.16B | $2.67B | $2.71B | $2.92B | $3.44B | $2.89B | $2.59B | $2.48B |
| Avg Forecast | $3.45B | $3.44B | $3.30B | $3.11B | $3.18B | $3.32B | $3.02B | $2.81B | $3.05B | $2.96B | $2.77B | $2.55B | $2.81B | $2.62B | $1.67B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
| High Forecast | $3.47B | $3.47B | $3.33B | $3.14B | $3.21B | $3.35B | $3.04B | $2.83B | $3.06B | $3.00B | $2.79B | $2.57B | $2.83B | $2.62B | $2.00B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
| Low Forecast | $3.41B | $3.41B | $3.27B | $3.09B | $3.13B | $3.29B | $2.99B | $2.78B | $3.04B | $2.91B | $2.75B | $2.52B | $2.78B | $2.62B | $1.34B | $3.71B | $4.06B | $3.76B | $3.30B | $3.43B | $3.75B | $3.61B | $3.06B | $3.43B | $3.72B | $3.60B | $3.01B | $3.10B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 0.87% | 0.78% | 1.24% | 0.77% | 0.80% | 0.70% | 0.80% | 0.71% | 0.84% | 0.74% | 0.88% | 0.85% | 0.93% | 0.80% | 0.86% | 0.80% |
GSK's average Quarter SG&A projection for Jun 23 is $2.77B, based on 1 Wall Street analysts, with a range of $2.75B to $2.79B. The forecast indicates a 29.37% rise compared to GSK last annual SG&A of $2.14B (Mar 23).
GSK EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $0.74 | $0.74 | $0.39 | $0.42 | $0.90 | $0.46 | $0.58 | $0.70 | $0.54 | $0.34 | $0.63 | $1.14 | $0.79 | $0.66 | $0.79 | $0.49 | $0.42 |
| Avg Forecast | $0.62 | $1.01 | $0.95 | $0.94 | $0.43 | $0.86 | $0.77 | $0.73 | $0.58 | $0.92 | $0.71 | $0.67 | $0.44 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
| High Forecast | $0.63 | $1.02 | $0.96 | $0.95 | $0.49 | $0.88 | $0.77 | $0.73 | $0.61 | $0.93 | $0.71 | $0.68 | $0.45 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
| Low Forecast | $0.62 | $1.00 | $0.94 | $0.93 | $0.32 | $0.84 | $0.77 | $0.73 | $0.54 | $0.90 | $0.70 | $0.66 | $0.44 | $0.81 | $0.53 | $0.60 | $0.49 | $0.59 | $0.40 | $0.43 | $0.47 | $0.62 | $0.40 | $0.64 | $0.52 | $0.68 | $0.50 | $0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.66% | 0.48% | 0.80% | 1.50% | 0.93% | 0.99% | 1.77% | 1.25% | 0.72% | 1.02% | 2.83% | 1.23% | 1.27% | 1.16% | 0.97% | 0.81% |
According to 1 Wall Street analysts, GSK's projected average Quarter EPS for Jun 23 is $0.71, with a low estimate of $0.70 and a high estimate of $0.71. This represents a -4.71% decrease compared to GSK previous annual EPS of $0.74 (Mar 23).
GSK Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BIIB | Biogen | $173.79 | $276.38 | 59.03% | Buy |
| GSK | GSK | $36.88 | $58.00 | 57.27% | Hold |
| MRK | Merck | $101.88 | $129.47 | 27.08% | Buy |
| BMY | Bristol-Myers Squibb Company | $54.32 | $64.57 | 18.87% | Hold |
| AZN | AstraZeneca | $71.42 | $84.33 | 18.08% | Buy |
| JNJ | Johnson & Johnson | $160.13 | $179.13 | 11.87% | Buy |
| SNY | Sanofi | $53.27 | $57.36 | 7.68% | Buy |
| NVS | Novartis | $109.35 | $116.33 | 6.38% | Hold |
| AMGN | Amgen | $319.22 | $293.15 | -8.17% | Buy |
| GILD | Gilead Sciences | $89.51 | $81.32 | -9.15% | Buy |
| ABBV | AbbVie | $203.55 | $174.04 | -14.50% | Buy |
GSK Forecast FAQ
Is GSK a good buy?
No, according to 10 Wall Street analysts, GSK (GSK) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 30.00% of GSK's total ratings.
What is GSK's price target?
GSK (GSK) average price target is $58 with a range of $36 to $85, implying a 57.27% from its last price of $36.88. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will GSK stock go up soon?
According to Wall Street analysts' prediction for GSK stock, the company can go up by 57.27% (from the last price of $36.88 to the average price target of $58), up by 130.48% based on the highest stock price target, and down by -2.39% based on the lowest stock price target.
Can GSK stock reach $60?
GSK's highest twelve months analyst stock price target of $85 supports the claim that GSK can reach $60 in the near future.
What are GSK's analysts' financial forecasts?
GSK's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $39.06B (high $39.37B, low $38.64B), average EBITDA is $11.04B (high $11.13B, low $10.92B), average net income is $5.71B (high $5.88B, low $5.44B), average SG&A $12.33B (high $12.43B, low $12.19B), and average EPS is $2.8 (high $2.88, low $2.67). GSK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $42.16B (high $42.49B, low $41.77B), average EBITDA is $11.91B (high $12.01B, low $11.8B), average net income is $7.2B (high $7.27B, low $7.11B), average SG&A $13.31B (high $13.41B, low $13.19B), and average EPS is $3.53 (high $3.56, low $3.49).
Did the GSK's actual financial results beat the analysts' financial forecasts?
Based on GSK's last annual report (Dec 2022), the company's revenue was $29.32B, which missed the average analysts forecast of $36.85B by -20.42%. Apple's EBITDA was $8.8B, missing the average prediction of $9.66B by -8.83%. The company's net income was $4.92B, missing the average estimation of $7.41B by -33.61%. Apple's SG&A was $8.37B, missing the average forecast of $10.81B by -22.57%. Lastly, the company's EPS was $2.44, beating the average prediction of $2.38 by 2.35%. In terms of the last quarterly report (Mar 2023), GSK's revenue was $6.95B, missing the average analysts' forecast of $8.07B by -13.86%. The company's EBITDA was $2.75B, beating the average prediction of $2.28B by 20.56%. GSK's net income was $1.49B, beating the average estimation of $1.37B by 9.07%. The company's SG&A was $2.14B, missing the average forecast of $2.55B by -15.86%. Lastly, the company's EPS was $0.74, beating the average prediction of $0.67 by 10.50%